Group 1 - The core viewpoint of the news is that Shenzhou Cell's stock has increased by 5.2%, reaching a price of 66.80 yuan per share, with a total market capitalization of 29.748 billion yuan [1] - Shenzhou Cell, established on April 23, 2007, and listed on June 22, 2020, focuses on the research and commercialization of biopharmaceutical products for various diseases, including malignant tumors and autoimmune diseases [1] - The company's main business revenue is entirely derived from product sales, accounting for 100% of its income [1] Group 2 - Among the top circulating shareholders of Shenzhou Cell, a fund under China Europe Fund, specifically the China Europe Medical Health Mixed A (003095), has entered the top ten shareholders, holding 2.3579 million shares, which is 0.53% of the circulating shares [2] - The China Europe Medical Health Mixed A fund has achieved a year-to-date return of 28.82% and a one-year return of 43.11%, ranking 2520 out of 8254 and 3274 out of 8037 respectively [2] Group 3 - The fund manager of China Europe Medical Health Mixed A is Ge Lan, who has a tenure of 10 years and 219 days, with the fund's total asset size at 39.908 billion yuan and a best return of 125.88% during her tenure [3] - Another fund manager, Zhao Lei, has a tenure of 60 days, managing assets worth 30.801 billion yuan, with a best return of 13.75% during his short tenure [3]
神州细胞股价涨5.2%,中欧基金旗下1只基金位居十大流通股东,持有235.79万股浮盈赚取778.12万元